Drug intelligence / Profile preview

glycerin + hypromellose + polyethylene glycol (Wills Eye Hospital)

Development stage: Unknown
Lead developer: Wills Eye Hospital
Modality: Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Small Molecules, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
Administration: Ophthalmic

Overview

This combination ophthalmic solution contains glycerin (0.2%), hypromellose (0.2%), and polyethylene glycol (1.0%), which function as lubricants and demulcents to protect and hydrate the ocular surface. In the clinical trial context provided by Wills Eye Hospital (NCT05514301), this formulation is utilized as a pharmacologically inactive placebo control to evaluate the safety and efficacy of netarsudil 0.02% ophthalmic solution in preventing proliferative vitreoretinopathy (PVR) in patients undergoing repair for rhegmatogenous retinal detachment (RRD). The ingredients work by stabilizing the tear film and providing a protective barrier over the corneal epithelium, thereby reducing irritation and dryness without exerting specific anti-fibrotic or rho-kinase inhibitory effects.

Other names: Artificial tearsGlycerin 0.2% / Hypromellose 0.2% / Polyethylene glycol 1% ophthalmic solution

Beyond the preview

Go deeper on glycerin + hypromellose + polyethylene glycol (Wills Eye Hospital).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on glycerin + hypromellose + polyethylene glycol (Wills Eye Hospital).

Explore the full profile